On Tuesday, Arrowhead Pharmaceuticals Inc (ARWR) stock saw a modest uptick, ending the day at $21.05 which represents a slight increase of $2.26 or 12.03% from the prior close of $18.79. The stock ...

($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall Street trimming price targets after the ...

Arrowhead Pharmaceuticals' stock rallied 17% due to significant pipeline developments and strategic partnerships. Learn more ...

Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...

RBC Capital analyst Luca Issi maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price target of ...

Stock futures edged lower on Tuesday as sentiment took a hit after President-elect Donald Trump said he would raise tariffs ...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.

Morgan Stanley analyst Michael Ulz maintained a Hold rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target ...

Arrowhead Pharmaceuticals is a biotechnology company focused on developing RNA interference (RNAi) therapeutics. Their proprietary platform, Targeted RNAi Molecule (TRiM™), allows them to target and ...

Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET. Company Participants. Vince Anzalone - VP, IR Chris Anzalone - Preside ...

Check the time stamp on this data. Updated AI-Generated Signals for Arrowhead Pharmaceuticals Inc. (ARWR) available here: ...